December 2014- Volume 10, Issue 12

December 2014

In this Issue

Business & Government Policy

On the cutting edge

On the cutting edge

A roundup of instrumentation, software and other tools and technology news

Aegerion acquires orphan drug Myalept for $325M

Aegerion acquires orphan drug Myalept for $325M

Commercialization of generalized lipodystrophy drug expected to bring synergy, near-term revenue

Certara awarded $400,000 by FDA

Certara awarded $400,000 by FDA

Three-year grant supports expansion of PBPK modeling platform

PDL BioPharma acquires bulk of Cerdelga royalty interest

PDL BioPharma acquires bulk of Cerdelga royalty interest

The company pays the University of Michigan $65.6 million for Gaucher disease treatment royalties

Discovery

Understanding East vs. West

Understanding East vs. West

Largest genomic study of liver cancer identifies mutations that distinguish Asian and Western disease

Personalized cancer therapeutics

Personalized cancer therapeutics

Felicitex Therapeutics and Selvita initiate strategic collaboration to target cancer quiescence

On the hunt against Huntington’s disease

On the hunt against Huntington’s disease

Charles River rides trending CRO growth, extends CHDI Huntington’s disease collaboration

High-throughput detection for discovery

High-throughput detection for discovery

Molecular Devices partners with Roche to develop custom ruthenium Nano-TRF detection platform

Preclinical

RNA delivery coming of age?

RNA delivery coming of age?

Data supportive of GEN-2 presented at the miRNA World Conference Workshop on miRNA delivery

Stopping the bleeding

Stopping the bleeding

Synthetic peptide-based device promotes hemostasis and healing

A French connection in oncology

A French connection in oncology

Innate Pharma describes cutaneous T cell lymphoma therapeutic in scientific journal Cancer Research

GVK BIO to acquire Vanta Bioscience

GVK BIO to acquire Vanta Bioscience

Deal provides GVK BIO with GLP toxicology services in several areas, including pharmaceuticals

Provantis helps increase efficiencies

Provantis helps increase efficiencies

Chinese research institute chooses Provantis’ preclinical software solution for Shanghai headquarters

Diagnostics

Waiting to exhale

Waiting to exhale

MIT finds new diagnostic tool in capnograph analysis of CO2 in patients’ breath

Urine test may prove to be golden

Urine test may prove to be golden

Data published in Cancer Discovery show ability to test tumor status from urine

A mind to predict diabetes

A mind to predict diabetes

Set of molecules found to link insulin resistance in the brain to diabetes

Myriad, AbbVie expand CDx agreement

Myriad, AbbVie expand CDx agreement

Deal comes on heels of positive study data on Myriad’s Tumor BRACAnalysis CDx

LabCorp sets $6.1B price tag on Covance

LabCorp sets $6.1B price tag on Covance

Companies say combined unit will be world’s leading healthcare diagnostics company

Research & Development

Making a difference with microtissue

Making a difference with microtissue

Seahorse Bioscience and Moffitt seek a method of metabolism measurement for cancer treatment

From stem cells to insulin-producing cells

From stem cells to insulin-producing cells

Harvard takes giant step toward new diabetes treatment, producing billions of beta cells from stem cells

Protein partnership

Protein partnership

Proteostasis Therapeutics and Astellas partner to modulate the unfolded protein response

Changing the cycle

Changing the cycle

Partnership between Idera and PPMD aims for Duchenne cure

NIH funds study of more than 200 rare diseases

NIH funds study of more than 200 rare diseases

Physician scientists at 22 consortia will collaborate with representatives of 98 patient advocacy groups to advance clinical research and investigate new treatments for patients with rare diseases

Compugen validates cancer immunotherapy prospect

Compugen validates cancer immunotherapy prospect

Company’s immune checkpoint candidate shows potential for development of multiple cancer immunotherapies

Feature

PepTalk welcomes you back to sunny San Diego

PepTalk welcomes you back to sunny San Diego

Conference offers an array of education, innovation and networking programs to help attendees gain new perspectives on the evolution of biologics

Q&A

Q&A: The year that was; the year that will be

Q&A: The year that was; the year that will be

DDNews speaks with two CEOs (Ron Squarer of Array BioPharma Inc. and Dr. Brad Thompson of Oncolytics Biotech) with an eye toward the recent past and near future of cancer therapeutics and life-sciences business trends

Commentary

Publishers' commentary: A decade down and more to come

Publishers' commentary: A decade down and more to come

DDNews’ publishers give you an update on why the magazine continues to thrive and how it serves the needs of you, the reader, as well as letting you know about some of the changes it has undergone over the past year, both in the physical issue and online

Working at science, science at work

Working at science, science at work

How can students best prepare for an actual career in life sciences? DDNews columnist Peter Kissinger attempts to sort out that tricky question.

Guest commentary: Clinical trial data inaccuracies--Challenges for personalized medicine

Guest commentary: Clinical trial data inaccuracies--Challenges for personalized medicine

Recent scrutiny puts trial results in question. How big is the problem, and what can be done to put things back on course?

Clinical Trials

In like FLINT

In like FLINT

Intercept drug tackles liver disease known as nonalcoholic steatohepatitis

Going after celiac disease

Going after celiac disease

BioLineRx declares Phase 1/2 study for new celiac treatment a success, but it won’t replace a gluten-free diet

A ClinIntel-ligent transaction

A ClinIntel-ligent transaction

PAREXEL boosts clinical RTSM offerings with ClinIntel buy

Celldex presents varlilumab proof-of-concept data

Celldex presents varlilumab proof-of-concept data

Favorable safety profile, clear immunological effects and clinical activity position therapeutic for future studies

Patient perspective

Patient perspective

Conference seeks inclusion of patient-focused endpoints in future brain cancer trials
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

March 2024 Issue Front Cover

Latest Issue  

• Volume 20 • Issue 2 • March 2024

March 2024

March 2024 Issue